secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001753926-24-001872
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical Q3 net loss $6.0M; $5M equity financing; GLP-1 implant study approved in Australia
--------------------------------------------------------------------------------

- Net loss $6.0M for Q3 2024 vs $6.8M YoY; cash $21.0M as of Sept 30, 2024.
- Regulatory approval in Australia for LIBERATE-1 Phase 1 trial of GLP-1 (exenatide) implant in obese/overweight patients.
- Private sale of 3.97M shares at $1.26/share to a director for $5.0M gross proceeds, extending runway into late 2025.
- Preclinical data: 82% sham-implant adjusted liver fat reduction and 20% weight loss comparable to semaglutide.
- R&D expense $4.2M (-5% YoY); G&A $2.1M (-22% YoY); operating expenses decreased $0.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001872/0001753926-24-001872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001872/vani-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer